U.S. Application Serial No. 10/040,830 Attorney Docket No.: 33677-00700



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Gary E. BORODIC <i>et al</i> .)	
Application Serial No.: 10/040,830)	Group Art Unit: 1645
Filed: January 8, 2002)	Examiner: Vanessa L. Ford
Title: The Use of Botulinum Toxin For The Treatment of Chronic Facial Pain)))	

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP RCE

Commissioner of Patents U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97(b), and in compliance with the duty of disclosure set forth in C.F.R. § 1.56, applicants are submitting herewith copies of references listed on the attached Forms PTO/SB/08A and PTO/SB/08B for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

Applicants' submission of the Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.

This Information Disclosure Statement is being filed with a Request for Continued Examination (RCE) and before receipt of a first office action. Therefore, it is respectfully submitted that

U.S. Application Serial No. 10/040,830 Attorney Docket No.: 33677-00700

no fee is required for consideration of this information. However, if any additional fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 13-3250 under referenced No. 33677.00700US.

Respectfully submitted,

Date: April 20, 2005

By:

Enrique D. Longton Designation No. 47.30

Registration No. 47,304

Customer No. 38647
MILBANK, TWEED, HADLEY & McCLOY LLP
1825 I Street, N.W., Suite 1100
Washington, DC 20006
Tel. No. (202) 835-7500
Fax No. (202) 835-7586

Approved for use through 07/31/2006. OMB 0651-0031

Complete if Known

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Application Number 10/040,830 Filing Date January 8, 2002 INFORMATION DISCLOSURE First Named Inventor Borodic Art Unit 1645 Examiner Name Vanessa L. Ford

STATEMENT BY APPLICANT (Use as many sheets as necessary)

Sheet_

33677.00700US Attorney Docket Number

			II S PATEN	T DOCUMENTS	
Exeminer Integris*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,869,610 B2	03/22/2005	Aoki et al.	
		US-			
-	l	US-			
		US-			•
		US-	1		
		US-			
		US-			
		US-			
		US-			
		US-			
	†	US-			
		US-			
		US-			
		US-		·	
		US-			
1	1	,	1	1	I

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	т6
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
			. .			

Examiner	Da	ate	
Signature		onsidered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Description of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known			
Substitute for form 1445/170	Application Number	10/040,830		
INFORMATION DISCLOSURE	Filing Date	January 8, 2002		
STATEMENT BY APPLICANT	First Named Inventor	Borodic		
(Use as many sheets as necessary)	Art Unit	1645		
(Use as many sneets as necessary)	Examiner Name	Vanessa L. Ford		
Sheet 2 of 2	Attorney Docket Number	33677.00700US		

NON PATENT LITERATURE DOCUMENTS Examiner Initials* Cite Initials* Cite Initials* Description: Borodic, Gary et al. "Botulinum toxin theraphy for pain and inflammatory disorders: mechanisms and therapeutic effects," Expert Opin. Investig. Drugs (2001) 10(8):1531-1544 Borodic, Gary et al. "Botulinum toxin therapy, immunologic resistance, and problems with available materials," Neurology 1996; 46:26-29				
Initials* No.¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Borodic, Gary et al. "Botulinum toxin theraphy for pain and inflammatory disorders: mechanisms and therapeutic effects," Expert Opin. Investig. Drugs (2001) 10(8):1531-1544 Borodic, Gary et al. "Botulinum toxin therapy, immunologic resistance, and			NON PATENT LITERATURE DOCUMENTS	
mechanisms and therapeutic effects," Expert Opin. Investig. Drugs (2001) 10(8):1531-1544 Borodic, Gary et al. "Botulinum toxin therapy, immunologic resistance, and		Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
			·	
Examiner Date	Evaminer	<u> </u>	Date	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.